The year in review: Highlights from 2014

Comments (0) Blog, News

by Charlie Litton, UNeMed | Dec. 31, 2014

Before moving forward it’s often useful to pause for a moment and reflect on the year that was. Here’s a review of some of the most important stories, developments, most popular posts and other highlights from UNeMed in 2014:

1. Jack Mayfield, 63

LO_jack_mayfield_2014We have been spoiled by the good fortune of having only happy news to share in the realm of medical research and development, so we were unprepared for the harsh reality of saying goodbye to our friend and colleague, Jack Mayfield, who suddenly passed in late October. It was a tough, bitter pill to swallow, and one we still lament today. The profound loss was a seismic event felt by everyone in our office, many others in the university system and even the region. By comparison, the remaining items on the following list seem trivial.

awards12. Innovation Week: 2014

One of the largest portions of traffic driving through the site was dedicated to information about our annual series of events called Innovation Week. We carried several stories about some of the innovations and research that were featured at Demo Day (see below), a seminar dedicated to fostering better collaborations between academia and industry, our annual open house, and a new scavenger hunt event. But the main event has always been the week-ending Innovation Awards Ceremony and Reception, which named Marius Florescu, M.D., the 2014 Emerging Inventor for technologies he’s working on associated with hemodialysis. The Most Promising Invention of 2014 was Jason MacTaggart’s, M.D., Aquablade, a high-pressure water jet that can safely cut tissue amid the flowing blood within the vasculature.

3. My first year: What everyone should know about tech transfer

As I completed my first year with UNeMed, I reflected on what I learned about the technology transfer industry. I came into the job with some preconceived notions that turned out to be plain wrong. The popularity of the post was a welcome surprise, but I think it’s also telling. Judging from the entirely positive feedback, most tech transfer offices operate under the same guiding principles and philosophies.

Caronda Moore4. Current treatments and innovative advances in diabetic research

Licensing associate Caronda Moore, PhD, penned a short blog about what we might soon see in the way of future breakthroughs for diabetes. Our office has been excited about a new gene transfer therapy for diabetics developed by Keshore Bidasee, PhD We were so impressed that it was our Innovation of the Year in 2013. The technology shows a lot of promise. In early testing, it appears to reverse a lot of the damage cause by diabetes, while lowering blood sugars levels. In this piece, however, Moore looks beyond Dr. Bidasee’s discovery to additional possibilities that might lie on the horizon.

5. Inflammation: The problem with heart disease and what we can do

Practicing cardiologist and researcher Dan Anderson, M.D., PhD, breaks down the core problem of coronary artery disease and how it leads to heart disease. In a fascinating and easy-to-understand examination of how heart disease progresses into a life threatening condition, Dr. Anderson also offers a sliver of hope that our ability to help more people may soon happen. Dr. Anderson is part of a team of UNMC researchers who are on verge of developing a new blood test that make heart disease entirely more predictable, and thus more preventable.

COPD Detection Platform Hardware6. The next big thing: Biomechanics and your smartphone

Fascinating research from the University of Nebraska at Omaha’s one-of-kind biomechanics facility inspired UNeMed’s business development manager, Joe Runge, to explore all that might be possible with something as ubiquitous as the smartphone. Runge’s thoughts appear to have been somewhat prescient, as several technologies are emerging from the labs of Nick Stergiou, PhD, that improve treatments or diagnostic abilities for a wide variety of ailments and conditions, including concussions, chronic obstructive pulmonary disorder, fall prevention in the elderly, or even autism. I suspect more detailed announcements about these technologies will populate next year’s list of top stories.

7. UNeMed shareholder meeting announces Shanghai office, success in 2014

D.J. Thayer and Bo Han, M.D., PhDBy all our measures, the 2014 Shareholder Meeting was a runaway success. While the meeting served several notable purposes, it also marked the first public announcement that UNeMed was expanding its operation to China with the establishment of UNeMed Health Consulting Services Shanghai, or UNMC China for short. Shortly after the brief announcement at the August shareholder meeting, UNeMed officially opened the doors to its Shanghai offices in October, and will use the presence to create more opportunities and stronger partnerships than ever before.

8. Why we care about the startup and entrepreneur communities

Superficially, this post was a look at a recent success story of UNMC technology resulting from UNeMed’s consistent and continued involvement in the startup and entrepreneur communities. But the popularity of the post speaks to the true intent of the piece, which was to highlight the importance of those communities and how tech transfer offices like ours would be wise to consider dedicating resources toward them. It takes patience and a long-view approach before any dividend can be expected, but building a biotech industry in a traditionally agronomic culture like Nebraska can’t happen overnight. But it can be done, and there is ample evidence showing Omaha is shifting towards more high-tech, high-growth industries like biotech.

9. Containing Ebola means we must care for the caregivers

Joe RungeNational media extensively covered the University of Nebraska Medical Center’s involvement with the treatment of Ebola patients who were infected while helping people in stricken Africa nations. When we first heard that Richard Sacra would be our first Ebola patient at the now world-renown biocontainment facility, we shared many of the conflicted emotions that everyone felt. But upon final examination, we were all proud to be associated with an institution that had the people, training, facilities and expertise to handle such patients. And as Joe Runge elegantly pointed out in this blog post, the best hope of containing the outbreak is to care for those frontline caregivers who bear the brunt of the risk as they try to save lives and comfort the afflicted.

Phillips screw head and driver10. Innovate to Innovate: New yardsticks needed to create new ideas

I found it remarkable — and worth writing about — the amount of smaller, lesser known innovations necessary just to get the big idea off the ground. It prompted a series of posts about researchers who must “innovate to innovate.” This was in the context of a researcher here, Marius Florescu, M.D., who had an idea for a better hemodialysis. Dr. Florescu thought he had a better way to help patients suffering kidney disease and failure and face regular dialysis treatments. Those patients often undergo a surgical procedure that connects a vein and artery, usually in the arm, becoming a portal that plugs into dialysis machines. Called an AV or arteriovenous fistula, these ports are complicated and prone to failure and complications. Dr. Florescu’s idea might solve some of those issues, but he had no way to prove it—until he invented a whole new process and procedure. The early success of the experiments, and subsequent industry interest, is part of the reason why Dr. Florescu was named the 2014 Emerging Inventor of the year.

Honorable Mention

Six new technologies featured at Demo Day 2014

The UNMC Technology Demonstration Day entered its second year during the 2014 Innovation Week festivities, and featured six promising innovations that have been licensed to existing companies, served as the basis of a new startup, or attracted intense interest from industry. The presentations were all videotaped and all but one are publicly available for viewing: Coronary artery disease biomarker; Labpoint middleware; COPD detection platform; hemodialysis catheter; laparoscopic training simulator. Acera Surgical declined to make public its presentation.

Nebraska Invests $100k in UNMC nanotech startup

We have a soft spot for ProTransit Nanotherapy, an Omaha-based biotech startup that was built off the innovations of a former UNMC researcher. It’s true, the company CEO, Gary Madsen, was our entrepreneur in residence as he founded the company, but the amazing ability of the technology and its potential to help people is why we go a little weak in the knees. And so we’re always excited to hear about Dr. Madsen and his fledgling operation reach a major milestone. He’s one-step closer to making things like sunscreen and cosmetics effective barriers against skin cancer, and he’s has other products in the pipeline that have shown some jaw-dropping results with testing in repairing damaged brain cells and spinal tissue. We are still years from seeing any of this outside the lab, but we’re happy to report that the progress thus far looks great.

UNeMed in the news

A new feature began last year highlighting the occasions when UNeMed, UNMC researchers or their inventions reached local, regional or national media. The page is growing into a long list of short blurbs that summarize the media mentions and link to the news items when possible. Some media links will inevitably break once outlets remove those stories from their servers, but we will continue to curate this popular new feature. We will try to replace those broken links with alternate versions as we become aware of them.

Classics

Several posts from previous years remain popular and relevant, in some cases more than a year after their original publication date — particularly those that focus on day-to-day operations and legal issues associated with intellectual property.

 

Read article

FREE LUNCH*

Comments (0) News

* Discussion about career options away from the bench will be provided.

freelunch2OMAHA, Neb. (Dec. 29, 2014)—On Thursday, Jan. 29, UNeMed will present, “Free Lunch,*”  a noon-time meal that people can eat without paying any money. A complimentary panel discussion about potential alternate career opportunities for scientists will also be provided.

Everyone is welcome to attend, but not everyone will receive free food. Register now to reserve your free food ticket, or join the waiting list in case there is extra free food. People who do not register or join the waiting list will almost certainly not get any free food.

“Free Lunch” and the panel discussion is a joint venture sponsored by UNeMed, the University of Nebraska Medical Center’s technology transfer office, and UNMC’s Postdoctoral Association.

Scheduled panelists are former UNMC graduate students and postdocs that have survived the lonely road of free-food hunting and now lead relatively happy and peaceful lives in the world of technology transfer and commercialization.

UNeMed president and CEO Michael Dixon, PhD; UNeMed vice president and director of marketing and licensing Steven Schreiner, PhD; and UNeMed licensing associate Agnes Lenagh, PhD, will discuss how their career paths began with scientific pursuits and led to their current work in the technology transfer business. The discussion will also likely cover other avenues away from the bench, and how others might follow a similar path.

—-

* Eaters of the free food are welcome to eavesdrop on any part of this discussion, and are even encouraged to ask questions, if they’re into that sort of thing. People who ask questions will receive a free UNeMed T-shirt that can be worn for many occasions, or used as a very large napkin while eating the free food. UNeMed T-shirts also look good on large pets, as makeshift lampshades, or as pillow cases on laundry day. Wearing a UNeMed T-shirt as a pair of pants has not been an appropriate use of any UNeMed T-shirt since 2007.

The panelists will also be very impressed if people eating the free food already have a UNeMed T-shirt. A person with a really old UNeMed shirt will probably be rewarded with a prize of some kind.

The exact nature of the free food has not yet been determined but officials have assured that it will be better than phoning in a platter of last-minute store-bought cookies, but not as great as a ribeye steak dinner.

The panel will be moderated by UNeMed communications associate Charlie Litton, who has absolutely zero scientific credentials, but is an expert eater of free food. Officials suggest that the busier he remains asking questions, the less likely it is that he will eat any of the free food.

UNeMed is not responsible for empty calories or injuries occurred during Free Lunch. All eaters will be eating at their own risk and there is no representation or warranty, express, implied, statutory or otherwise.

Read article

Five cancer researchers recruited to Buffett Cancer Center

Comments (0) News

Bring in more than $5 million in funding

by Tom O’Connor, UNMC

OMAHA, Neb. (Dec. 5, 2014)—The Fred & Pamela Buffett Cancer Center at the University of Nebraska Medical Center and its clinical partner, Nebraska Medicine, has added five new translational cancer researchers to its staff in recent months.

Located at 45th Street and Dewey Avenue, the Fred & Pamela Buffett Cancer Center is scheduled to open in 2017.

Fred & Pamela Buffett Cancer CenterThe recruits hail from some of the nation’s top scientific and medical institutions. Collectively, they bring more than $5 million in cancer research funding to Nebraska. All have begun their work at the Fred & Pamela Buffett Cancer Center during the past four months.

“When we launched this ambitious project to build the world’s finest cancer center right here in Omaha, we believed that it would attract the very best minds in cancer research from around the world,” said Ken Cowan, M.D., PhD, director of the Fred & Pamela Buffett Cancer Center.

“These recruits exemplify that vision. We are building a place where pioneering scientific exploration will shape the future of cancer science and medicine – and these recruits are just the start.”

The $323 million Fred & Pamela Buffett Cancer Center – the largest construction project ever on the medical center campus – will create approximately 1,200 jobs at the medical center alone, plus thousands of others in construction and related industries. In total, the project will provide 4,657 new jobs to the metro area, infusing $537 million annually into the economy on an ongoing basis.

As translational cancer researchers, these new recruits conduct research that applies discoveries generated in the laboratory directly to patients’ bedsides.

The new recruits are:

Nick Woods, PhD

  • Recruited from H. Lee Moffitt Cancer Center in Tampa, Fla. Joined the Fred & Pamela Buffett Cancer Center on Oct. 1.
  • Has a $400,000 National Institutes of Health (NIH)/National Cancer Institute (NCI) grant in breast cancer.
  • A Fairfield, Neb., native and cancer survivor, Dr. Woods’ primary research interest is systems biology based analysis of protein-protein interactions networks associated with cancer signaling pathways to identify novel targets for cancer therapies. His future goals are to examine acute myeloid leukemia signaling pathways associated with Fanconi Anemia proteins.
  • For more information on Dr. Woods, click here.

Michael Green, PhD

  • Recruited from Stanford University. Joined the Fred & Pamela Buffett Cancer Center on Nov. 1.
  • Has a $195,000 grant funded by The Leukemia & Lymphoma Society.
  • Green works to identify and understand the genetic alterations that give rise to lymphoma and allow it to evade the immune system. He is interested in the genetics of B-cell lymphoma, with the goal of using genetic profiling to understand disease biology and inform treatment decisions.
  • For more information on Dr. Green, click here.

Amar Singh, PhD

  • Recruited from Vanderbilt University. Joined the Fred & Pamela Buffett Cancer Center on Oct. 1.
  • Has a $1.65 million National Institutes of Health grant in colon cancer.
  • Brought one other PhD level researcher with him to Nebraska.
  • Singh’s research focuses on understanding the role of the tight junction proteins, claudins, in the regulation of barrier function, colonic inflammation and neoplastic transformation and growth in correlation with the EGF receptor signaling.
  • For more information on Dr. Singh, click here.

Punita Dhawan, PhD

  • Recruited from Vanderbilt University. Joined the Fred & Pamela Buffett Cancer Center on Oct. 1.
  • Has a $950,000 Veteran’s Affairs Health Grant in colon cancer
  • Recruited one additional PhD postdoctoral fellow from Chicago.
  • Dhawan focuses her research on claudins, metastasis, tumorigenesis, signal transduction and trafficking, and cell death and differentiation.
  • For more information on Dr. Dhawan, click here.

Rebecca Oberley-Deegan, PhD

  • Recruited from National Jewish Hospital in Denver. Joined the Fred & Pamela Buffett Cancer Center on Aug. 1.
  • Has a $1.65 million National Institutes of Health/National Cancer Institute grant in prostate cancer
  • Oberley-Deegan’s research examines the role of oxidative stress and inflammation in the context of radiation and cancer biology. Her laboratory previously has shown that a catalytically active antioxidant can protect normal prostate tissues during radiation, but not prostate tumor tissues. The focus of her research is to determine the mechanisms by which antioxidants can protect normal tissues from radiation while simultaneously making the tumor vulnerable to radiation damage.
  • For more information on Dr. Oberly-Deegan, click here.

The Fred & Pamela Buffett Cancer Center is a National Cancer Institute (NCI) designated cancer center — a distinction held by only 68 centers in the country. It is the only NCI-designated center in the state of Nebraska. The Fred & Pamela Buffett Cancer Center is also one of the 13 founding members of the National Comprehensive Cancer Network (NCCN), an alliance of the world’s leading cancer centers. This recognition means the most current and innovative treatment options are available to cancer center patients through the integration of cutting-edge research into state-of-the-art care. Cancer center physicians and scientists work together to quickly translate discoveries made in the laboratory into innovative treatments for the patient.

Read article

Linder highlights UNeMed success in halftime show, again

Comments (0) News

IOWA CITY, Iowa (Dec. 4, 2014)—Jim Linder, interim president of the University of Nebraska, spotlighted UNeMed during a five-minute halftime interview in the Nebraska Cornhuskers’ final football broadcast of the regular season on Friday, Nov. 28.

Greg Sharpe (left) and interim president of the University of Nebraska chat about the value of the University to the state during a pre-rocrded interview that aired during the Nebraska-Iowa football game last week.

Greg Sharpe (left) and interim president of the University of Nebraska Jim Linder chat about the value of the University to the state during a pre-recorded interview that aired during the Nebraska-Iowa football game last week.

Shortly before Nebraska completed its 17-point comeback in a 37-34 overtime win over Big 10 rival Iowa, Linder chatted for five minutes with the “Voice of the Huskers,” Greg Sharpe, the Husker Sports Network’s prime broadcast play-caller since 2008.

Linder told Sharpe that the University helps drive the state economy by pushing innovations to the marketplace. He used UNeMed as an example, noting the more than 400 new UNMC inventions at UNMC in the last five years.

“More important than numbers are the new products that could change lives: New therapies for diabetes, cancer, Parkinson’s.” Linder said.

Linder has been a regular feature during all radio broadcasts of Nebraska football games, and wrapped the regular season Friday in an interview that demonstrated the whole value of the University to the state. The interview revisited several subjects touched on in previous weeks, including the work performed by healthcare providers at the University of Nebraska Medical Center in their high-profile battles against Ebola.

“I’m proud of the commitment of our physicians and staff at UNMC and TNMC for their work in caring for Ebola patients,” Linder said during the pre-recorded interview, adding that UNMC is now “a national model for Ebola care.”

Linder, who led UNeMed from 2006-2011, also talked about the Fred and Pamela Buffet Cancer Center, the University’s booming enrollment, and the Innovation Campus’ focus on food, fuel and water.

Read article

More to tech transfer than meets the eye

Comments (0) Blog

by Tyler Mueller, UNeMed | Nov. 24, 2014

When I first told people about my internship, I really didn’t know what to say.

Tyler Mueller

Tyler Mueller

It was before I had even started working there. Before I went in for the interview, I visited the website and thought I had a pretty good idea of what UNeMed did. I kept seeing the same description over and over again; “The technology transfer office.” Most people didn’t know what this meant so I just told them “they’re like the salesmen for research at the university.”

Now I can safely say there’s so much more to it than that.

Every business has the primary goal of profit. But this feels different. Everyone works hard with each other and the researchers at the university. The staff is passionate about their career and it shows through their work. They take it seriously because what they do can affect the world and they strive for it.

Admittedly, it was a bit overwhelming at first. The staff is incredibly educated. And with all those degrees, I figured everyone would be wealthy. To me, licensing and selling life-saving treatments would be one of the most profitable markets. But they’re not working for that paycheck each week; they are working for the satisfaction that their work can change the world and make it a better place.

This same attitude is reflected through stories on the website and speakers at the shareholder meeting. Technology transfer offices are about helping people, how creative and innovative people can be. The shareholder meeting wasn’t about how much money they were making. The focus was on these amazing technologies they have already started licensing and already started working towards the end goal of helping a patient.

Not every technology licensed at the university is designed to save lives. Some technologies simply eliminate the hassle of a task in the lab. But they all serve a purpose, with some having the potential change the world.

When I think about what technology transfer means to me, I don’t think about salesmen or profits anymore. I think about new ideas, new technologies, new treatments, new medicines, and new procedures and how to we take that and get it to the masses and those who need it. We edge closer and closer towards a time when the problems of today can be solved tomorrow.

Read article

Nebraska invests $100k in UNMC nanotech startup

Comments (1) News

ProTransit Nanotherapy

ProTransit Nanotherapy president and CEO Gary Madsen, PhD, (center) shows off a vial of prototypes that could one day be incorporated into skin care products such as sunscreen and cosmetics. The nanoparticles, formulated by scientists Bala Vamsi Karuturi, PhD,(left) and Steve Curran (right), are vehicles that can deliver powerful antioxidants to the deepest layers of skin where they can help prevent skin cancer, wrinkles and blemishes. (Photo: Charlie Litton/UNeMed)

by Charlie Litton, UNeMed

OMAHA, Neb. (Nov. 21, 2014)—A biotech startup in Omaha reached a major milestone, completing its first round of fundraising and inched a step closer to providing skincare products that prevent skin cancer, wrinkles and other blemishes. The investment also keeps hope alive the company will be able to expand as intended to create applications that can treat brain damage caused by stroke and even heal spinal cord damage.

ProTransit Nanotherapy, a company based on a technology invented at the University of Nebraska Medical Center, announced Monday a $100,000 investment from Invest Nebraska, a program administered by the state’s Department of Economic Development that focuses on fostering high-growth, high-paying industry startups and small businesses in Nebraska.

ProTransit Nanotherapy’s location on UNMC campus and its place in Omaha’s growing biotech industry were factors in Invest Nebraska’s decision. But Mark Crawford, Invest Nebraska’s CEO and investment manager, said the largest factor was about ProTransit’s co-founding president and CEO, Gary Madsen. Crawford said he “invests in people, not companies.”

Mark Crawford_LO

Mark Crawford

“What attracted us to Gary was that he’s a seasoned biotech CEO,” Crawford said. “Gary’s decision to start his company in Nebraska shows the growth of our ecosystem.”

Madsen—the former entrepreneur in residence at UNMC’s technology transfer office, UNeMed—said Invest Nebraska gave his fledgling company the final push it needed.

“That’s going to allow us to really get up and running here in this laboratory, buying equipment, and buying supplies,” Madsen said.

ProTransit Nanotherapy will begin development of bench-scale products, and move nanoparticle production to Omaha from the Cleveland Clinic in Ohio, where co-founder and inventor Vinod Labhasetwar, PhD, now works.

Already, ProTransit employs 2.5 full-time positions, including skilled and highly-specialized scientists, Steve Curran and Bala Vamsi Karuturi.

“The really good thing is both of these guys have worked on exactly these type of nanoparticles before,” Madsen said. “I never thought I would find anyone like that, and here’s two of them right on campus.”

Steve Curran

ProTransit Nanotherapy’s Steve Curran demonstrates part of the process for building the nanoparticles that could one day make skin care products much more effective in preventing skin cancer, wrinkles and blemishes. ProTransit is an Omaha startup company based on technology invented at the University of Nebraska Medical Center. (Photo: Charlie Litton/UNeMed)

Before joining ProTransit, Curran and Karuturi worked in laboratories of Dr. Joseph Vetro in the College of Pharmacy, specializing in building the type of nanoparticles that Madsen expects will deliver powerful antioxidants to the deepest layers of skin.

Dangerous UV light from the sun, chemicals, smoke, smog and even the natural aging process create free radicals within the skin. If unchecked, free radicals bang around inside the tissue, damaging cells, which leads to things like wrinkles, blemishes and even cancer. Antioxidant enzymes are known to be an effective treatment against free radicals, but stabilizing and getting the enzymes to where they’re needed has been the tricky part.

Developed by a former UNMC researcher, Dr. Labhasetwar, ProTransit’s nanoparticles essentially serve as a delivery vehicle that can reach places within the human system that others can’t. That means antioxidant enzymes can finally penetrate to the deepest layers of skin where they can do the most good, Madsen said.

“Up till now,” Madsen said, “the problem with the enzymes is they don’t penetrate the skin, and they’re really unstable. They last for just a few minutes.”

By enclosing the enzymes in a harmless, biodegradable nanoparticle, Dr. Labhasetwar not only stabilized the enzymes, but also created a slower, more gradual release.

ProTransit dermal therapy

Once formulated, the nanoparticles made by ProTransit Nanotherapy look like a fine white powder.

Applying a skin product with ProTransit’s technology could have a lasting effect that battles free radicals for weeks after just one application. Finding out just how long and how effective will be part of the early round of testing. Testing for the skin care products will be done on artificial skin and tissue cultures grown in a lab.

Madsen was also involved in securing a recent $1.2 million grant from the Nebraska Research Initiative at the University of Nebraska to upgrade and purchase new equipment in the biologics production facility. That money is being used to equip the nanoparticle pilot plant that Madsen—along with UNMC researchers on other projects—is using for early-stage production.

Madsen said he expects to move into a phase-two round of fundraising where he will need an estimated $1.2 million to scale-up the process, and fully develop the skincare product. Although one of the world’s largest cosmetic manufacturers is already expressing interest in ProTransit’s first product line, it will likely be several years before it will be available on store shelves, Madsen said.

Invest Nebraska could see a return on its investment as soon as 2016. The investment is a two-year convertible note, which means after two years Invest Nebraska could seek repayment with interest. Or, if ProTransit Nanotherapy starts selling stock at any point within the next two years, Invest Nebraska could convert the loan into a share of company ownership at a discounted rate.

dermis second dayexport

Read article

UNeMed opens office in Shanghai

Comments (1) News, Success Stories

UNMC-China Ribbon Cutting

Chinese and University of Nebraska Medical Center officials cut the ribbon to UNMC-China on Oct. 29, 2014. UNMC-China is a subsidiary of UNeMed, the technology transfer office for UNMC. Pictured from left are Deloitte’s Maria Liang; UNMC vice chancellor for business and finance Don Leuenberger; UNeMed’s director of international and domestic business affairs D.J. Thayer; and UNMC’s director of the Asia Pacific Rim Development Program, Jailin Zheng. (UNMC Photo: Lisa Spellman)

by Charlie Litton, UNeMed

SHANGHAI, China (November 7, 2014)—The University of Nebraska Medical Center’s relationship with China formed a stronger bond with the official opening of a satellite office in the Shanghai Free Trade Zone.

A ribbon-cutting ceremony on Oct. 29 officially opened the door to deeper biomedical cooperation between UNMC and Chinese sectors in biomedical industry and healthcare education.

“Collaboration with China’s biomedical industry and higher education is really the essence of our strategy,” said D.J. Thayer, UNeMed’s Director of International and Domestic Business Affairs, who oversaw the creation of UNMC-China.

UNMC-China will focus on three core areas: Improve international collaborations, share knowledge, and commercialize UNMC innovations in a vast Chinese marketplace that lives in the world’s second largest economy.

“This is taking what we do best, and combining it with what they do best,” Thayer said. “We’re good at a lot of things, but not everything. Everyone benefits from this. Nebraskans, Americans, the Chinese. Everyone.”

D.J. Thayer

UNMC recently celebrated the 10th anniversary of its relationship with China, which has been based largely on educational exchange and research collaborations.

Opening a fully-staffed operation in Shanghai expands that relationship for greater collaborations with Chinese medical schools and hospitals. The new office opens a path to a wider range of possibilities for commercializing UNMC technologies and developing partnerships with industrial partners in China.

UNMC already has a long track record of successful student and faculty exchanges, as well as several UNMC inventions licensed to Chinese companies.

But UNMC will also expand its focus abroad to consulting with Chinese officials and developers who are increasingly trying to provide more Western-styled healthcare options. Already, UNMC-China is meeting with Chinese architectural and engineering firms on a $3 billion project that would create a massive health care facility for a piece of the growing medical tourism market.

UNMC-China is a subsidiary of UNeMed Corporation, the technology transfer and commercialization office for UNMC. UNMC-China is known officially as UNeMed Health Consulting Shanghai, or UHCS for short.

Read article

Sillman, Fenster win scavenger hunt

Comments (0) Innovation Week, News

by Tyler Mueller, UNeMed

Graduate students Brady Sillman and Danielle Fenster won the first scavenger hunt of UNeMed’s Innovation Awards, an annual celebration honoring UNMC researchers, faculty, students and staff for their ideas, inventions and discoveries.

To win the scavenger hunt, contestants had to follow clues to complete questions, answer trivia on UNeMed’s social media pages, and even post a few “selfies” to social media.

Brady Sillman

“I knew that I wanted to do something to help people.” Brady Sillman

Sillman and Fenster complete the scavenger hunt in a tie for first place. But winning the scavenger hunt isn’t the only thing Sillman and Fenster have in common. Both were inspired by loved ones to pursue a career in research.

Sillman, a graduate student in Pharmacology and Experimental Neuroscience, came to UNMC for the institution’s “great reputation and world-renown program.” Sillman’s sister inspired him to join the medical research community. She has cerebral palsy, an incurable disorder that affects muscle tone, movement, and motor skills.

“I knew that I wanted to do something to help people,” Sillman said. “It wasn’t until I joined a small research lab at UNO and got first-hand experience in the lab that I knew that I finally found my way of contributing.”

Danielle Fenster

“My great-grandmother had Alzheimer’s and I wanted to help others like her.” Danielle Fenster

Fenster is also a graduate student in Pharmacology and Experimental Neuroscience. Fenster joined UNMC after having a great experience working in Keshore Bidasee’s lab in the summer research program. Fenster was also inspired by a loved one.

“My great-grandmother had Alzheimer’s and I wanted to help others like her,” said Fenster.
When asked for advice for new students, Sillman said to get involved on campus. “Get involved in intermural sports or the Graduate Student Association. The more involved you get, the better you’ll be connected.”

Fenster said to think carefully when choosing a lab for research. “Find something you’re passionate about,” she said. “It will be a long couple of years if you dislike your lab or research.”

Read article

Jack Mayfield, 63

Comments (2) Blog, News

Jack Mayfield

Jack Mayfield was most visible on campus during Innovation Week, usually snapping pictures.

by Charlie Litton, UNeMed

The small office where Jack Mayfield churned out agreements and licensing contracts at near prolific rates remains dark today.

Jack fell from an apparent heart attack Tuesday. By Friday the 63-year-old was gone.

Jack joined UNMC in 2012, working as a contracts specialist in the technology transfer office, UNeMed. Any researcher, student, staff or faculty who ever needed a quick contract drawn up to share materials or protect confidentiality, probably worked with Jack.

LO_jack_mayfield_2014But to ask anyone who worked with him, few mention his chops as a lawyer. In fact his unequaled production rarely even rates a mention. More often we use words like “mentor” and “teacher” and “friend.” And of course we talk about his passions: Photography and cycling, pursuits he chased with vigor and vitality.

Jack was perhaps most visible as a regular fixture during UNeMed’s Innovation Week, relentlessly snapping photos of anyone and everyone who stood still long enough. Long before joining UNeMed, Jack ran a successful photography business in Tennessee, and he was always willing to lend his skills whenever asked.

I knew Jack best as photographer, because that’s a part of what I do.

In the most basic terms photography is about light. It’s about capturing and preserving the light of a moment. As simple as it sounds, understanding what needs to be done to capture light can be intensely complicated. Particularly in the days of celluloid, when Jack was firing at top speed as the “Pictureman.”

Capturing the light is in many ways easier now with the instant feedback that digital provides, but the basic principle remains the same. Whether it’s lining up silver iodide crystals or ones and zeroes: Capture the light, preserve the moment.

I would like to know how many moments in time he captured, shooting countless rolls of film at graduations, parties and who knows what else. How many of those are now cherished memories for the smiling faces he popped with a flash and shutter? How many scrapbooks, picture frames and even forgotten shoe boxes in attic spaces are populated with those time capsules he created?

He gave each of those people some small measure of immortality, and in so doing achieved it for himself. I’m grateful that he shared with me some of how he did that.But no part of Jack was larger than his enthusiasm for cycling. A member of an Omaha bike club, the Dundee Chain Gang, Jack logged somewhere on the order of 9,000 miles in 2013. For the record, if you wanted to drive from New York to L.A., you’d log about 2,700 miles. From Omaha, that 9,000 miles would get you to somewhere between India and Inner Mongolia.

After every long weekend of even longer rides—marathons, really—Jack would recount the exhausting trips with glee. And he had photos too. The new pictures of Jack and his rider-buddies—beaming under their bike helmets in all their spandex glory—would find a special place on his bulletin board. Some of the pictures are a little dog-eared and ever-so-slightly faded from the morning sun that creeps into his east-facing office.

His office is dark now, but those happy pictures are still there—taken in some far off place where the hills were steep climbs, but the glide down to the finish must have been worth every exhausting pump and kick.

Visitation is Tuesday, Nov. 4, 6-8 p.m. at Heafey-Heafey-Hoffmann-Dworak & Cutler, 7805 West Center Road, Omaha, Neb.. Funeral services are Wednesday, Nov. 5, at 10:30 a.m. at Christ Lutheran Church in Louisville, Neb.

Read article

Florescu, MacTaggart honored at Innovation Awards

Comments (2) Innovation Week, News, Success Stories

by Tyler Mueller, UNeMed

awards1OMAHA, Neb. (Oct. 24, 2014)—Marius Florescu, M.D., took home the 2014 Emerging Inventor award, while Jason MacTaggart, M.D., received the Most Promising New Invention award during UNeMed’s eighth annual Innovation Awards Ceremony and Reception Thursday afternoon at the University of Nebraska Medical Center.

Florescu_091614_cropped_LO

Dr. Florescu

An estimated 203 attended the Innovation Awards ceremony, the culmination of UNeMed’s Innovation week, where researchers such as Drs. Florescu and MacTaggart are honored and celebrated for their inventions and discoveries. UNeMed also honored all the UNMC staff, students, and faculty who received a U.S. patent, licensed an innovation or reported a new invention during the last fiscal year.

Dr. Florescu, an associate professor in the nephrology division of UNMC’s Department of Internal Medicine, received the Emerging Inventor award for two his recent inventions: A hemodialysis catheter and a device to improve the arteriovenous or AV fistula.

The new hemodialysis catheter tube is designed with a small balloon that can expand to remove the build-up that naturally grows into a mass that blocks flow. Florescu’s innovative design would significantly lower the cost of removing the blockage by eliminating the need for additional procedures.

Jason MacTaggart, M.D.

Dr. MacTaggart

The new design for the AV fistula is the first major improvement in 40 years in the area. AV fistulas are made by surgically creating a portal between a vein and artery, usually in the wrist, for patients who must undergo regular hemodialysis.

Dr. MacTaggart, an assistant professor in the vascular surgery section of UNMC’s Department of Surgery, was awarded the Most Promising New Invention for his new surgical tool, the AquaBlade. The AquaBlade is designed to cut tissue amid flowing blood using highly-pressurized water. The device can also be used to remove stents in blood vessels. The AquaBlade is less invasive, thereby lowering the risk factor associated with heart surgery and speeding up the recovery process for the patient.

Divya Bhagirath was the 2014 winner of a free iPad.

Divya Bhagirath was the 2014 winner of a free iPad.

“Considering all of the other outstanding work and creativity demonstrated by many of my colleagues here at UNMC, this award is a great honor for me and my collaborators,” Dr. MacTaggart said via email. “We can’t thank our friends at UNeMed and people like my chairman of surgery, Dr. [David] Mercer, enough  for helping facilitate the work that led to this award, as it is their unwavering support of our research that allow us to conceive and refine inventions like the AquaBlade.”

UNeMed also awarded prizes to the winners of the first ever scavenger Hunt, which went to Brady Sillman and Danielle Fenster who tied for first place.
Divya Bhagirath was the lucky winner of the free iPad.

Read article

Six new technologies featured at Demo Day 14

Comments (1) Innovation Week, News

by Tyler Mueller, UNeMed

OMAHA, Neb. (Oct. 21, 2014)—Attendees got a look at some of the innovative technologies developed in the labs at the University of Nebraska Medical Center during UNeMed’s Technology Demonstration Day Tuesday afternoon.

Demo Day, part of UNeMed’s Innovation Week, featured six technologies presented to an estimated audience of 70. The new technologies are either the foundation of a new startup company, are licensed to an existing company, or are under negotiations for a licensing deal. (Videos of the presentations can be viewed here.)

Technologies featured were a new blood test for diagnosing of heart disease; a new laparoscopic simulator; an improved hemodialysis catheter; data management software; a COPD detection platform; and a next-generation surgical mesh.

Dan Anderson, M.D., PhD

Dan Anderson, M.D., PhD

Dan Anderson, M.D., PhD, kicked-off the event by presenting a new biomarker that could be used to create a new blood test. Under development at UNMC, the blood test could help flag people who are candidates for serious heart trouble even when other tests say otherwise.

Seventy percent of people at the age of 40 have coronary artery disease. But it doesn’t always develop into a fatal condition. A blood test using the biomarker—malondialdehyde-acetaldehyde adduct, or MAA for short—could help care providers tell the difference, Anderson said.

“It’s a failure of medicine to die from a heart attack at 40,” Dr. Anderson said.

With a simple blood test, doctors can analyze a patient’s blood and look for a ratio of MAA antibodies. Similar ratios could also be link with other inflammatory diseases, Anderson said.

Ron Allen

Ron Allen

Ron Allen, CEO of Chrysalis, presented a new catheter designed to reduce risk for patients who undergo the process that filters a patient’s blood, hemodialysis.

Two million people are on hemodialysis, a necessary treatment for patients with failing kidneys that takes three hours, three times a week. For most patients, they either take the treatment or die.

“There are no positive alternatives,” Allen said, adding the only other option is no treatment at all.

Blood flow in the catheter can become blocked, requiring surgery and radiological imaging to verify the repair. When a catheter does need to be replaced, the entire procedure can cost up to $18,000. The new catheter, an elegantly simple design by UNMC’s Marius Florescu, M.D., reduces the number of times a catheter needs to be replaced. Dr. Florescu incorporated a small balloon into the tip of the catheter that can be inflated to disrupt the blockage and eliminate the need for additional procedures and costs.

Jenna Yentes, PhD

Jenna Yentes, PhD

Jenna Yentes, PhD, presented a new method developed by UNO’s Nick Stergiou that can detects the deadly episode that come from narrowed or or destroyed tissue in the lungs—a condition known as chronic obstructive pulmonary disease, or COPD. The third leading cause of death in the United States, COPD is an unpredictable condition that creates sometimes deadly flare-ups or exacerbations that are impossible to diagnose.

Using a device attached to the chest and feet, the device takes measurements of walking and breathing and how the two biorhythms interact with one another.

This ratio of walking and breathing can alert the patient to early signs of exacerbation, the flare-up of symptoms that speeds the destruction of the lung.

John Glock

John Glock

John Glock, president and founder of Labpoint, shared his solution for sharing information between medical institutions. Labpoint improves the communication between labs, clinics and hospitals sharing critical information despite using different hardware and software.

The system, called ELIRT, works by monitoring and transmitting data from one entity to another. The server is installed on the user’s computer and integrates with the user’s software. Once identified through filters, data can be shared externally.

Joe Runge

Joe Runge

Joe Runge introduced a new laparoscopic simulator developed at UNMC, which cuts down costs and space requirements. Laparoscopic simulators are used to train and maintain skills for laparoscopic surgeons but require dedicated space and several thousand dollars.

The new portable system renders usable nearly any open space for the simulator at a fraction of the cost, enabling surgeons or students to practice more often. The system can also rate or grade the user and show what areas they need to work on.

Matthew MacEwan, president of Acera Surgical, ended Demo Day with a presentation on a new design for surgical meshes for use in brain surgery.

Matthew MacEwan

Matthew MacEwan

The surgical mesh, CeraFix™ Dural Substitute, is the flagship product of Acera Surgical, and is paving the way for next generation surgical materials.

Surgical meshes are used to treat damaged tissue, but with a fail rate of 10-40 percent, it’s not the most economical treatment for patients or hospitals.

The CeraFix™ Dural Substitute is designed to promote more rapid cellularization of neuro tissue. It has a cloth-like feel and design, but is strong enough to treat damaged tissue before being resorbed. This cuts down on the costs to replace the surgical mesh in previous designs if it breaks or if the tissue doesn’t fully heal itself.

Innovation Week concludes Thursday, Oct. 23, with the Innovation Awards Ceremony and Reception in the DRC I Auditorium at 4 p.m.

 

Read article

Innovation Week seminar discusses building better partnerships

Comments (0) Innovation Week, News

Toru Seo, PhDOMAHA, Neb. (Oct. 21, 2014)—Academic researchers and pharmaceutical companies seem perfectly suited for one another.

Where pharma appears to show weakness, academia shows strength. And where academia is weak, pharma is strong. The differences in overall mission between both are stark, but they are a near perfect counterbalance.

It would seem the university “yin” and the industrial pharmaceutical “yang” should yield fruitful research collaborations.

Yet, it’s no secret that there’s often dysfunction between the two.

Pharmaceutical executive Toru Seo, PhD, set out Tuesday afternoon to explain why that is, and offered a few simple measures for building better partnerships. The talk was part of UNeMed’s annual celebration of UNMC research, Innovation Week, which culminates with the Innovation Awards on Thursday, Oct. 23.

“Being a scientist,” Dr. Seo said, “I want to help people in academia because I know how hard it can be.”

Seo, who earned a doctorate in molecular and cellular pathobiology from Wake Forest University, was assistant professor at Columbia University and is now deputy general manager for licensing and business development at Taisho Pharmaceutical in Tokyo, Japan.

Drug discovery and development is increasingly more reliant on often cash-strapped academic researchers, while pharmaceutical R&D departments scale back budgets or narrow their scope. The changing dynamic means productive collaborations between industrial and academic partners is more important than ever.

“We have to have steady pipeline, and in order to have a steady pipeline we have to do better R&D,” Seo said.

When academic-industrial collaborations fail, it “almost always” lies at the feet of disagreements and misunderstandings center on intellectual property, goals, metrics or deliverables, he said.

The obvious fix is better communication, but Seo said the communications must first focus on the science. Identifying common goals, setting clear, detailed expectations for outcomes and providing timely feedback all build an engaged and transparent relationship—two critical elements that can’t exist without clear and consistent communication.

Seo closed his discussion with a quote former Fed Chairman Alan Greenspan. In a 2004 speech in Chicago, Greenspan said:

“I have found no greater satisfaction than achieving success through honest dealing and strict adherence to the view that, for you to gain, those you deal with should gain as well.”

Read article

Dixon interviewed during Nebraska halftime

Comments (0) News

UNeMed President Michael Dixon (left) looks over his notes during his halftime interview with Greg Sharpe (right), which was broadcast Saturday night during Nebraska's 38-17 win over Northwestern.

UNeMed President Michael Dixon (left) looks over his notes during his halftime interview with Greg Sharpe (right), which was broadcast Saturday night during Nebraska’s 38-17 win over Northwestern.

LINCOLN, Neb. (Oct. 18, 2014)—UNeMed president and CEO Michael Dixon and the interim president of the University of Nebraska, Jim Linder, were featured guests during the halftime intermission of Nebraska’s 38-17 victory over Northwestern University.

Linder, a regular feature of all Nebraska football game broadcasts, brought in Dixon to discuss the value of tech transfer and commercialization efforts at the University, and how they impact the local economy.

“In the past three years, we’ve helped create eight startup companies that have raised more than $10 million to help support technology development,” Dixon told Greg Sharpe during the pre-recorded interview. “Our activity, along with startup support groups like NMotion, Straight Shot, PIPELINE, and Silicon Prairie News has organizations like CNN Money declaring Omaha as one of the top startup hubs in the nation.”

The interview was broadcast by the Husker Sports Network, carried locally by KFAB (1110 AM) in Omaha. Linder’s series of halftime interviews continues this week, when he brings in Sam Meisels, the executive director of the Buffett Early Childhood Institute. Nebraska will host Big Ten newcomer Rutgers. Kickoff is listed at 11 a.m.

 

 

Read article

First ever scavenger hunt to begin Monday

Comments (0) Innovation Week, News

Scavenger HuntOMAHA, Neb. (Oct. 17, 2014)—Kicking off at 9 a.m. on Monday, October 20, participants must complete challenges and hunt down answers to questions on the entry form. These challenges will be completed for points and a chance to win a price. The scavenger hunt will conclude at 4:59 p.m. on Wednesday, October 22.

Answers to the scavenger hunt must be submitted in the allotted timeslot to the unemed@unmc.edu inbox. For each correct answer, participants will receive one point. Some of the questions will require a selfie while a simple written answer will suffice for others. Creativity is highly encouraged and even rewarded.

Bonus points are offered to participants who follow UNeMed on Facebook and Twitter and answer the trivia questions posted each day. Answers should be submitted by replying to @unemed and tagging the post with #IWeek14.

Selfies for Scavenger HuntThe first participant with the highest amount of points will receive prizes. The scavenger hunt is open to all UNMC staff, faculty, and students.

Monday, October 20 marks the start of Innovation Week, which begins with an Open House in the DRC Atrium from 9-11 a.m. The Bioscience Week Kick-Off Reception at Baird Holm, will be from 4-6 p.m. On

Tuesday, October 21 there will two events; a seminar presented by Taisho Pharmaceutical Co.’s Deputy General Manager for Licensing and Business Development from 10-11 a.m. and “Demo Day” featuring six UNMC and UNO leading technologies from 3-5 p.m.

On Wednesday, BioNebraska will present “Experiencing Biotechnology,” a panel discussion hosted by UNL’s Department of Biochemistry at the Beadle Center in Lincoln.

Innovation Week will come to a close on Thursday, October 23 with the Awards Ceremony in the DRC Auditorium at 4 p.m.

Read article

Demo Day will feature coronary artery disease discovery

Comments (0) Innovation Week, News

OMAHA, Neb. (Oct. 17, 2014)—Promising research could lead to a significant and dramatic improvement in correctly diagnosing unstable coronary artery disease years, perhaps even decades, before traditional methods.

A scientific research journal, PLOS One, published in its September issue an article by a team of scientists at the University of Nebraska Medical Center who found a biomarker that could “allow for the assessment of a future cardiovascular event.”

The article—”Unique Antibody Responses to Malondialdehyde-Acetaldehyde (MAA)-Protein Adducts Predict Coronary Artery Disease“—significantly concludes that a biomarker could tell the difference between patients who harbor stable or unstable coronary artery disease. The difference between the two groups is the difference between living well into old age or suffering a sudden fatal heart attack at 40-years-old. Stable coronary artery disease is a manageable condition, but the unstable version is unpredictable and nearly impossible to diagnose.

An interdisciplinary team of researchers at the University of Nebraska Medical Center in Omaha—Michael Duryee (left), Geoff Thiele (center) and Dan Anderson (right)—believe they found a way to determine who will develop potentially deadly heart disease with a simple blood test.

An interdisciplinary team of researchers at the University of Nebraska Medical Center in Omaha—Michael Duryee (left), Geoff Thiele (center) and Dan Anderson (right)—believe they found a way to determine who will develop potentially deadly heart disease with a simple blood test.

Lead author and project collaborator, Dan Anderson, M.D., PhD, will discuss the research and its possible implications during UNMC Technology Demonstration Day on Oct. 21. Anderson, who is also a practicing cardiologist, will be among six others presenting some of the most recent and advanced innovations developed at UNMC and UNO laboratories.

Anderson and UNMC colleagues Geoffrey Thiele, PhD, and Michael Duryee are working on developing a simple blood test for the biomarker, which could give patients potentially years of advance warning if they carry the unstable version of the disease.

Such an early diagnosis could dramatically change how cardiologists treat patients, advancing cardiac care to an improved, more targeted and personalized approach.

Hosted by UNeMed, the technology transfer office at UNMC, Demo Day is a part of Innovation Week, a celebration of the research, discovery and innovation at UNMC. Demo Day is aimed at a general audience and is free and open for anyone to attend. Registrations are requested.

Read article

Qian Zhang promoted, will lead international efforts

Comments (0) News

LO_qian_zhang_2014OMAHA, Neb. (Oct. 16, 2014)—UNeMed announced today that postdoctoral licensing associate Qian Zhang, PhD, has been promoted to a new and permanent full-time position with UNeMed as the International Technology Development Specialist.

With the new job, Dr. Zhang will focus more on international tele-medicine and forming international relationships.

“I’m very excited for the new job. It has a broader scope in terms of responsibilities,” Dr. Zhang said.

Born in Linyi, China, Dr. Zhang attended graduate school at the University of Nebraska Medical Center where she briefly considered an academic research career. After earning her doctorate in cancer biology in 2011, Dr. Zhang joined UNeMed as an intern. UNeMed soon offered her a one-year appointment as a postdoctoral licensing associate, where she helped evaluate and bring UNMC innovations to the market.

“We are incredibly pleased to have Dr. Zhang fill this position,” said Michael Dixon, president and CEO of UNeMed. “Dr. Zhang’s experience and knowledge of global markets, specifically China and Japan, allow us access to a multitude of international companies that are interested in partnering and investing in our new technology.”

As an important staff member, Dr. Zhang has been assisting UNeMed in international markets. Fluent in Chinese, Dr. Zhang has helped UNeMed create connections with businesses in foreign markets.

Dr. Zhang was also a recipient of the 2014 Howard Bremer Scholarship from the Association of University Technology Managers.

Dr. Zhang is currently working on her MBA at the University of Nebraska at Omaha and expects to receive her diploma in December 2014.

Read article